Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized study of axitinib with or without dose titration in metastatic renal cell carcinoma
2008-007786-23Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of axitinib in renal cell carcinoma (RCC) (3 arms), sponsored by Pfizer. Primary endpoint: Objective response rate. Started Feb 2009; status: completed.
02
Drugs
axitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2008-007786-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007786-23.